Healthcare & Diagnostics

Clinical-grade hormonal intelligence at the point of care.

Yohafly's healthcare programme brings hormonal diagnosis and fertility-stage tracking to women in remote and underserved regions — building on SERB POWER–funded research (Grant No. SPG/2022/000681) into a non-invasive, self-administered system.

This system is under active research and development (project timeline to 2026) and is not yet a commercially available or regulatory-cleared medical device.

The Clinical Problem

A Common, Under-Diagnosed Barrier to Fertility

PCOS is among the most prevalent drivers of infertility, affecting an estimated 5–18% of women of reproductive age, with prevalence in India reported between 3.7% and 22.5%. Diagnosis depends on detecting hormonal imbalance, traditionally requiring repeated clinic visits and lab blood work — a barrier for women far from diagnostic infrastructure.

Side-by-side diagram of the normal menstrual cycle versus the PCOS cycle along the hypothalamus–pituitary–ovary axis.
In PCOS, a skewed LH:FSH ratio disrupts ovulation. Yohafly's biosensing approach targets AMH, LH and FSH to support earlier detection at the primary-care level. See the research gallery →
How the System Works

Phase I — Built & Bench-Validated

Phase I (Dec 2023 – Mar 2025) delivered a complete point-of-care pipeline, built and bench-tested.

01
Built

Serum-Separation Centrifuge

A 3D-printed, battery-powered portable centrifuge enabling reliable serum separation outside a central lab.

02
Built

Microfluidic ELISA Cassette

An automated microfluidic cassette that runs the ELISA assay on-device for AMH, LH, and FSH.

03
Built

Spectrophotometric Readout

A miniaturised ~450 nm spectrophotometric module with Beer–Lambert firmware for AMH/LH/FSH quantification.

04
Built

Cloud Web App

A cloud web app for reports, trend tracking, and teleconsultation, built on Yohafly's low-power, offline-capable stack.

Bench validation: AMH 1.82 ng/mL · FSH 3.11 mIU/mL · LH 1.23 mIU/mL, benchmarked against Roche Diagnostics — bench results, not a clinical or regulatory claim.

What's Next

Phase II — In Development (Target Jul–Sep 2026)

Phase II adds label-free electrochemical biosensing, on-device AI, and a multi-hormone panel — extending the Phase I platform toward field deployment.

05
Planned

EIS Biosensing

Label-free electrochemical impedance spectroscopy (EIS) biosensing on antibody-functionalised graphene screen-printed electrodes, for a multi-hormone panel (AMH/LH/FSH/testosterone) from a single fingerprick.

06
Planned

AI/ML Risk Prediction

PCOS risk prediction from impedance features plus age, BMI, and LH:FSH ratio. Models are currently being trained on simulated data, pending clinical validation.

07
Planned

Mobile App & Teleconsultation

A Tamil/English mobile app covering ANC/PNC tracking and teleconsultation, paired with IoT dashboards for remote follow-up.

08
Planned

AMTZ Integration & Village Deployment

Integration and benchmarking at AMTZ, followed by deployment across 15 villages in Trichy District.

Platform Fit

Designed for Offline, Edge-AI Operation

The programme is designed for on-device processing and offline capability, so the system can work where connectivity and clinical staff are scarce — consistent with the ESP32 / TinyML stack used across Yohafly's products, including the flagship Portable Hormone Analyser.

Wider Healthcare Capabilities

Beyond the Fertility-Stage Programme

👁️

Dry Eye Disease Wearable (Observant)

An ESP32-BLE, canthus-mounted wearable sensing device designed to monitor indicators associated with Dry Eye Disease, supporting earlier detection and ongoing management.

🏥

Point-of-Care Rural Diagnostics

Compact diagnostic devices engineered for primary-care and rural settings where centralized lab access is limited, enabling on-site results without specialist infrastructure.

📡

Remote Patient Monitoring

Connected monitoring tools that extend follow-up care beyond the clinic, built on the same low-power, offline-capable connectivity stack used across Yohafly's devices.

Research Foundation

Backed by research: SERB POWER Grant SPG/2022/000681, Kongunadu College of Engineering and Technology — PI Dr. Yogapriya Jaganathan; Co-Is Dr. C. Saravanabhavan and Dr. Preethi Palanisamy (2023–2026).

The team's work, "An Integrated Framework for Women's Fertility Stage Analysis Using AI and IoT-Driven Technologies," was published in the ICEIE 2024 proceedings (ISBN 978-93-6163-096-5), funded by DST-SERB. Dr. Yogapriya also received the Best Keynote Speaker award at the 9th Annual Congress on PCOS and Fertility, London, 27–28 Nov 2025.

View grant details in Research & Grants →  ·  See the research gallery →

Recognition

Award & Industry Recognition

🏆

Best Keynote Speaker Award

Dr. Yogapriya received the Best Keynote Speaker Award at the 9th Annual Congress on PCOS and Fertility, London (27–28 Nov 2025) — formally acknowledged by ANRF, with a Certificate of Recognition from Conference Series (UK) and five indexed journals.

🤖

AMTZ Medical Robotics Hackathon

Selected among the top 9 at the First Global Hackathon on Medical Robotics (WHIF, AMTZ Visakhapatnam, 12–13 Dec 2025), leading to a confirmed 1-year incubation at the AMTZ Robotics Healthcare Centre.

🏛️

Infosys TechZooka 2025

Participated in Infosys TechZooka / Technology Summit 2025 (MCity), showcasing the Phase I prototype to industry.

Field Validation

Grounded in Clinical Practice

Alongside lab and bench testing, the team has consulted endocrinologists, fertility specialists, and diagnostic laboratories to benchmark the prototype against established reference assays (including TSH and AMH ELISA) and to align the design with real-world clinical workflows. This consultation is ongoing as the system moves toward clinical validation.

Research Journey

Engaging Clinicians Across South India

The research team has engaged with fertility specialists, endocrinologists, and diagnostic labs across Tamil Nadu, Karnataka, and Kerala to ground the device's design in real clinical practice.

Tamil Nadu
Consultations with fertility specialists on current diagnostic pathways for PCOS and hormonal-stage assessment, and how a point-of-care device could fit into existing clinical workflows.
Karnataka
Discussions with diagnostics teams on reference assay methods (TSH, AMH ELISA) and how a portable system could complement central-lab testing.
Kerala
A visit to a diagnostics laboratory to review instrumentation, sample-handling practice, and reporting workflows informing the prototype's design.
Flagship Context

How This Fits the Yohafly Platform

The Portable Hormone Analyser remains Yohafly's flagship product and primary near-term focus. The healthcare programme on this page represents the broader diagnostic-platform context that the Analyser is built within — sharing its sensor design discipline, embedded AI/firmware, and clinical-grade software approach. These are presented as supporting platform context, not as a repositioning away from the Analyser.

Discuss a Healthcare Deployment or Collaboration

Get in touch to discuss pilot programs, partnerships, or technical due diligence for healthcare and diagnostics applications.

Request a Briefing Back to All Sectors